

February 16, 2021

SRL Diagnostics Private Limited: Update on Entity

Summary of rating(s) outstanding

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Outstanding
Fund-based Limits	15.00	15.00	[ICRA]A&
Short-term interchangeable	(15.00)	(15.00)	[ICRA]A1&
Non-fund Based Limits	2.00	2.00	[ICRA]A&/A1&
Total	17.00	17.00	

*Instrument details are provided in Annexure-1; &: on watch with developing implications

Rationale

ICRA has taken a consolidated view of SRL Limited (SRL) and its subsidiaries (including SRL Diagnostics Private Limited, or SRLD) because of operational and functional synergies between the entities.

Material Event

The board of directors of SRLD's ultimate parent company, Fortis Healthcare Limited (Fortis), in their meeting held on February 5, 2021, gave their approval to SRL to acquire 50% stake in its existing Joint Venture (JV), DDRC SRL Diagnostics Private Limited (DDRC-SRLD), for a cash consideration of Rs. 350 crore (including the ownership of the DDRC brand). DDRC-SRLD is an existing 50:50 JV between the DDRC Group and SRLD, which operates a diagnostics services business in Kerala through a network of eight central labs and 194 stat labs. Following the acquisition, DDRC-SRLD will become a 100% subsidiary of SRL. The consummation of the transaction is subject to the company's shareholders approval and other regulatory approvals as required.

Impact of the Material Event

DDRC-SRLD is engaged in providing diagnostics services and generates most (~70%) of its business from the B2C segment with focus on providing relatively less complex range of diagnostic tests. Accordingly, its business profile is similar to that of SRL. With revenues of Rs. 160.4 crore (in FY2020) and a network of 202 labs spanning the state, DDRC-SRLD commands a leading market position in Kerala within the organised diagnostics segment. The company recorded revenues of Rs. 204.1 crore in 9M FY2021 (65.9% YoY growth) aided by increased Covid-19 tests during the period.

In ICRA's view, the acquisition provides SRL an opportunity to expand its presence in other markets in South India (where it currently has limited presence) besides consolidating its leadership position in Kerala. The acquisition also complements its strategy of growing the B2C business segment and expanding DDRC-SRLD's product portfolio (lifestyle diseases, specialised tests and preventive packages) with more specialised and complex tests besides harnessing cost synergies through common material sourcing opportunities and integration of other functions.

The acquisition of DDRC-SRLD is credit neutral for SRL as ICRA believes that the acquisition will not have a material impact on the financial profile of SRL owing to limited reliance on external borrowings (Rs. 100-125 crore) to fund the acquisition. The company aims to fund a sizeable part of the acquisition through existing cash reserves (Rs. 256.4 crore as on December 31, 2020). The company's credit profile continues to remain characterised by a strong balance sheet, healthy cash flow generation from existing operations and negligible borrowings. Over the medium term, the acquisition is expected to enhance the company's scale and profitability besides improving its market share among the organised diagnostic players.

Please refer to the following link for the previous detailed rationale that captures key rating drivers and their description, liquidity position, and rating sensitivities: [Click here](#)

Analytical approach

Analytical Approach	Comments
Applicable Rating Methodologies	Corporate Credit Rating Methodology Rating Methodology for Healthcare Diagnostic Service Providers
Parent/Group Support	Parent/Group Company: SRL Limited ([ICRA]A&/A1&); 100% stake in SRLD.
Consolidation/Standalone	The ratings are based on the consolidated financial statements of the issuer.

About the company

SRL Diagnostics Private Limited, formerly known as Piramal Diagnostic Services Private Limited, is one of the largest chains of clinical diagnostic centres in India. It is a wholly owned subsidiary of SRL Limited, which is owned by Fortis Healthcare Limited (57.7% stake). SRLD is one of the few diagnostic centre chains offering pathology and radiology services on a pan India level. Most centres, in addition, offer echocardiography, ECG, stress tests, pulmonary function tests, audiometry and body composition tests, besides pathology and radiology tests. SRLD operates 35 labs and 26 collection centres (as on September 30, 2020). Additionally, through its joint venture, DDRC SRL Diagnostic Services, it operates 203 labs and four collection centres in Kerala.

In FY2020, the company reported a turnover of Rs. 277.2 crore with a profit after tax (PAT) of Rs. 25.4 crore. At the consolidated level, the SRL Group reported a consolidated turnover of Rs. 1,010.3 crore with a PAT of Rs. 78.9 crore.

Key financial indicators (audited)

SRL Consolidated	FY2019	FY2020
Operating Income (Rs. crore)	1,003.7	1,010.3
PAT (Rs. crore)	85.9	78.9
OPBDIT/OI (%)	17.3%	16.9%
PAT/OI (%)	8.6%	7.8%
Total Outside Liabilities/Tangible Net Worth (times)	0.1	0.2
Total Debt/OPBDIT (times)	0.0	0.4
Interest Coverage (times)	30.0	13.4

PAT: Profit after Tax; OPBDIT: Operating Profit before Depreciation, Interest, Taxes and Amortisation

Source: Company, ICRA Research; All ratios as per ICRA calculations

Note: Amount in Rs. crore

SRLD Standalone	FY2019	FY2020
Operating Income (Rs. crore)	282.3	277.2
PAT (Rs. crore)	27.0	25.4
OPBDIT/OI (%)	27.1%	26.8%
PAT/OI (%)	9.6%	9.2%
Total Outside Liabilities/Tangible Net Worth (times)	5.0	2.7
Total Debt/OPBDIT (times)	1.7	1.7
Interest Coverage (times)	4.0	3.8

PAT: Profit after Tax; OPBDIT: Operating Profit before Depreciation, Interest, Taxes and Amortisation

Source: Company, ICRA Research; All ratios as per ICRA calculations

Note: Amount in Rs. crore

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

	Instrument	Type	Current Rating (FY2021)				Chronology of Rating History for the past 3 years								
			Amount Rated (Rs. crore)	Amount Outstanding (Rs. crore)	Date & Rating in		Date & Rating in FY2020	Date & Rating in FY2019		Date & Rating in FY2018					
					Dec 29, 2020 Feb 16, 2021	Apr 24, 2020		Feb 1, 2019	Apr 12, 2018	Mar 9, 2018	Feb 13, 2018	Feb 7, 2018	Dec 28, 2017	Jul 17, 2017	Jul 4, 2017
1	Fund based facilities	Long Term	15.0	NA	[ICRA]A&	[ICRA]A-&	[ICRA]BBB+ (Stable)	[ICRA] BBB- (Stable)	[ICRA] BBB- (Negative)	[ICRA] BBB@	[ICRA] BBB+@	[ICRA] A-@	[ICRA] A-&	[ICRA] A-&	[ICRA]A- (Stable)
2	Short term fund based interchangeable	Short Term	(15.0)	NA	[ICRA]A1&	[ICRA]A1&	[ICRA]A2	[ICRA]A3	[ICRA]A3	[ICRA] A3+@	[ICRA] A2@	[ICRA] A2+@	[ICRA] A2+&	[ICRA] A2+&	[ICRA] A2+
3	Non-fund based facilities	Long and Short Term	2.00	NA	[ICRA]A&/A1&	[ICRA]A-&/A1&	[ICRA]BBB+ (Stable)/ A2	[ICRA] BBB- (Stable)/ A3	[ICRA] BBB- (Negative) / A3	[ICRA] BBB@/ A3+@	[ICRA] BBB+@/ A2@	[ICRA] A-@/ A2+@	[ICRA] A-&/ A2+&	[ICRA] A-&/ A2+&	[ICRA]A- (Stable)/ A2+

&= Under watch with developing implications

Complexity level of the rated instrument

ICRA has classified various instruments based on their complexity as "Simple", "Complex" and "Highly Complex". The classification of instruments according to their complexity levels is available on the website www.icra.in

Annexure-1: Instrument details

ISIN No	Instrument Name	Date of Issuance / Sanction	Coupon Rate	Maturity Date	Amount Rated (RS Crore)	Current Rating and Outlook
NA	Fund based facilities	NA	NA	NA	15.00	[ICRA]A&
NA	Short term fund based interchangeable	NA	NA	NA	(15.00)	[ICRA]A1&
NA	Non-fund based facilities	NA	NA	NA	2.00	[ICRA]A&/ A1&

Source: Company

Annexure-2: List of entities considered for consolidated analysis

Company Name	Ownership	Consolidation Approach
SRL Limited	Parent Company	Full Consolidation
SRL Diagnostics Private Limited	100.00%	Full Consolidation
SRL Diagnostics FZ-LLC	100.00%	Full Consolidation
SRL Diagnostics (Nepal) Private Limited	50.00%	Equity Method
DDRC SRL Diagnostics Private Limited	50.00%	Equity Method
SRL Reach Limited	100.00%	Full Consolidation

Source: Company

Note: ICRA has taken a consolidated view of the parent (SRL), its subsidiaries (including SRLD) and JVs while assigning the ratings.

ANALYST CONTACTS

Subrata Ray

+91 22 6114 3408

subrata@icraindia.com

Arushi

+91 124 4545 396

arushi@icraindia.com

Shamsher Dewan

+91 124 4545 300

shamsherd@icraindia.com

Sruthi Thomas

+91 124 4545 822

sruthi.thomas@icraindia.com

RELATIONSHIP CONTACT

Jayanta Chatterjee

+91 80 4332 6401

jayantac@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited



Registered Office

1105, Kailash Building, 11th Floor; 26 Kasturba Gandhi Marg; New Delhi 110001
Tel: +91 11 23357940-50



Branches



© Copyright, 2021 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.